These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion. Guervil DJ; Rosenberg AF; Winterstein AG; Harris NS; Johns TE; Zumberg MS Ann Pharmacother; 2011 Jul; 45(7-8):861-8. PubMed ID: 21712506 [TBL] [Abstract][Full Text] [Related]
4. A comparative trial of anti-factor Xa levels versus the activated partial thromboplastin time for heparin monitoring. Vandiver JW; Vondracek TG Hosp Pract (1995); 2013 Apr; 41(2):16-24. PubMed ID: 23545756 [TBL] [Abstract][Full Text] [Related]
5. Management of pregnant women with mechanical heart valve prosthesis: thromboprophylaxis with low molecular weight heparin. Abildgaard U; Sandset PM; Hammerstrøm J; Gjestvang FT; Tveit A Thromb Res; 2009 Jul; 124(3):262-7. PubMed ID: 19162303 [TBL] [Abstract][Full Text] [Related]
7. Is the monitoring of anti-Xa activity necessary in pregnant women undergoing thromboprophylaxis? O'Connell MP; O'Leary M; MacKeogh L; Murphy K; Keane DP Eur J Obstet Gynecol Reprod Biol; 2004 May; 114(1):12-4. PubMed ID: 15099863 [TBL] [Abstract][Full Text] [Related]
8. Prophylactic dosing adjustment in pregnancy based upon measurements of anti-factor Xa levels. Gyamfi C; Cohen R; Desancho MT; Gaddipati S J Matern Fetal Neonatal Med; 2005 Nov; 18(5):329-31. PubMed ID: 16390793 [TBL] [Abstract][Full Text] [Related]
9. Monitoring Unfractionated Heparin (UFH) therapy: which Anti-Factor Xa assay is appropriate? Ignjatovic V; Summerhayes R; Gan A; Than J; Chan A; Cochrane A; Bennett M; Horton S; Shann F; Lane G; Ross-Smith M; Monagle P Thromb Res; 2007; 120(3):347-51. PubMed ID: 17118432 [TBL] [Abstract][Full Text] [Related]
10. Achieving target antifactor Xa activity with a heparin protocol based on sex, age, height, and weight. Rosborough TK; Shepherd MF Pharmacotherapy; 2004 Jun; 24(6):713-9. PubMed ID: 15222660 [TBL] [Abstract][Full Text] [Related]
11. A randomized comparative study of using enoxaparin instead of unfractionated heparin in the intervention treatment of coronary heart disease. Chen JL; Chen J; Qiao SB; Guo YL; Wu YJ; Dai J; Yuan JQ; Qin XW; Yang YJ; Gao RL Chin Med J (Engl); 2006 Mar; 119(5):355-9. PubMed ID: 16542576 [TBL] [Abstract][Full Text] [Related]
12. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Levine MN; Hirsh J; Gent M; Turpie AG; Cruickshank M; Weitz J; Anderson D; Johnson M Arch Intern Med; 1994 Jan; 154(1):49-56. PubMed ID: 8267489 [TBL] [Abstract][Full Text] [Related]
13. Monitoring heparin anticoagulation in the acute phase response. Uprichard J; Manning RA; Laffan MA Br J Haematol; 2010 May; 149(4):613-9. PubMed ID: 20230412 [TBL] [Abstract][Full Text] [Related]
14. Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin. Vandiver JW; Vondracek TG Pharmacotherapy; 2012 Jun; 32(6):546-58. PubMed ID: 22531940 [TBL] [Abstract][Full Text] [Related]
15. Thrombin formation and effect of unfractionated heparin during pediatric cardiac catheterization. Chen D; Långström S; Petäjä J; Heikinheimo M; Pihkala J Catheter Cardiovasc Interv; 2013 Jun; 81(7):1174-9. PubMed ID: 22915548 [TBL] [Abstract][Full Text] [Related]
16. Anti Xa monitoring during treatment with low molecular weight heparin or danaparoid: inter-assay variability. Kitchen S; Iampietro R; Woolley AM; Preston FE Thromb Haemost; 1999 Oct; 82(4):1289-93. PubMed ID: 10544915 [TBL] [Abstract][Full Text] [Related]
17. Discordant aPTT and anti-Xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin. Price EA; Jin J; Nguyen HM; Krishnan G; Bowen R; Zehnder JL Ann Pharmacother; 2013 Feb; 47(2):151-8. PubMed ID: 23386070 [TBL] [Abstract][Full Text] [Related]
18. Unfractionated heparin dosing requirements in the presence of inflammation during the first six months of life. Heizer JW; Schardt TQ; Murphy ME; Branchford BR Thromb Res; 2019 May; 177():17-22. PubMed ID: 30844684 [TBL] [Abstract][Full Text] [Related]
19. Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis. Harenberg J; Stehle G; Blauth M; Huck K; Mall K; Heene DL Semin Thromb Hemost; 1997; 23(1):83-90. PubMed ID: 9156415 [TBL] [Abstract][Full Text] [Related]
20. In vivo age dependency of unfractionated heparin in infants and children. Newall F; Ignjatovic V; Summerhayes R; Gan A; Butt W; Johnston L; Monagle P Thromb Res; 2009 Mar; 123(5):710-4. PubMed ID: 18829072 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]